HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction

morningstar.com·Jul 16, 2026 · 3 h fa

Spinogenix Announces World Health Organization Approval of "Codabakalner" as International Nonproprietary Name for SPG601

morningstar.com·Jul 10, 2026 · 6 g fa

Priority Review Granted to PD-L1/4-1BB Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in EP-NEC

morningstar.com·Jul 15, 2026 · 1 g fa

Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthma

morningstar.com·Jul 13, 2026 · 3 g fa

Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB